We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
-14.15%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$5.67B
AUM Growth
-$1.54B
Cap. Flow
+$155M
Cap. Flow %
2.74%
Top 10 Hldgs %
45.45%
Holding
105
New
10
Increased
9
Reduced
7
Closed
8

Top Buys

Rank Stock Value
1
LIAN
LianBio American Depositary Shares
LIAN
+$87.4M
2
BLU
BELLUS Health Inc.
BLU
+$67.9M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$59.2M
4
RLMD icon
Relmada Therapeutics
RLMD
+$44.5M
5
XLO icon
Xilio Therapeutics
XLO
+$34.1M

Top Sells

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$190M
2
TGTX icon
TG Therapeutics
TGTX
+$49M
3
VERV
Verve Therapeutics
VERV
+$23.9M
4
CTMX icon
CytomX Therapeutics
CTMX
+$17.8M
5
WHWK
Whitehawk Therapeutics
WHWK
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.05%
2 Financials 0.78%
3 Miscellaneous 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCUL icon
101
Ocular Therapeutix
OCUL
$2.24B
– –
-750,000
Closed -$7.5M
VRDN icon
102
Viridian Therapeutics
VRDN
$2.47B
– –
-1,034
Closed -$17K
OKUR
103
OnKure Therapeutics
OKUR
$119M
– –
-6,222
Closed -$464K
WHWK
104
Whitehawk Therapeutics
WHWK
$233M
– –
-347,668
Closed -$10.2M
CCXI
105
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-218,532
Closed -$3.74M
1 2 3 4
5

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, RA Capital Management held 105 positions worth $5.67B, down 21% from $7.22B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

RA Capital Management's Q4 2021 filing shows 10 new, 9 increased, 7 reduced and 8 closed positions. Its largest new stake was LianBio American Depositary Shares: 7,655,015 shares worth $47.2M. The largest sale was Atea Pharmaceuticals, an estimated $190M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials and Miscellaneous.

  • RA Capital Management's largest Q4 2021 buy was LianBio American Depositary Shares: 7,655,015 shares worth $47.2M.
  • RA Capital Management added most to Ascendis Pharma A/S in Q4 2021, an estimated $26.8M increase.
  • RA Capital Management's biggest Q4 2021 reduction was TG Therapeutics, cutting an estimated $49M.
  • RA Capital Management fully exited Atea Pharmaceuticals in Q4 2021, selling an estimated $190M.
  • RA Capital Management's ten largest holdings make up 45% of its $5.67B portfolio in Q4 2021.
  • RA Capital Management opened 10 new positions and closed 8 in Q4 2021.
  • RA Capital Management's portfolio value fell 21% quarter-over-quarter to $5.67B.

Based on RA Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.